Le Thuy, Jerel David, Bryan Locke J
Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA.
Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Ther Adv Hematol. 2021 Apr 9;12:20406207211006027. doi: 10.1177/20406207211006027. eCollection 2021.
Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols. Targeting of the PI3K pathway remains a valuable treatment across both hematologic and solid malignancies. There are currently four United States Food and Drug Administration (FDA)-approved PI3K inhibitors, with several others in development. Copanlisib is a pan-PI3K inhibitor currently FDA-approved for the treatment of relapsed/refractory follicular lymphoma (FL) following two lines of therapy. Since FDA approval, there have been further investigations into the long-term safety profile of copanlisib, as well as treatment of FL and other lymphoma subtypes, both indolent and aggressive. Here, we review the most recent available data from clinical trials, describe the management of the most common side effects, and explore future concepts. The use of copanlisib as part of a combination therapy for various hematologic malignancies will also be discussed. Copanlisib is a unique drug compared with other PI3K inhibitors, with remarkable potential to improve our armamentarium in cancer treatment.
血液系统恶性肿瘤的临床研究随着治疗理念的不断涌现和临床方案结果的逐步演变而持续推进。PI3K通路靶向治疗在血液系统恶性肿瘤和实体瘤中仍然是一种有价值的治疗方法。目前有四种美国食品药品监督管理局（FDA）批准的PI3K抑制剂，还有几种正在研发中。库潘尼西是一种泛PI3K抑制剂，目前已获FDA批准，用于在接受两线治疗后复发/难治性滤泡性淋巴瘤（FL）的治疗。自获得FDA批准以来，对库潘尼西的长期安全性以及FL和其他淋巴瘤亚型（包括惰性和侵袭性）的治疗进行了进一步研究。在此，我们回顾了临床试验的最新可用数据，描述了最常见副作用的管理，并探讨了未来的概念。还将讨论库潘尼西作为各种血液系统恶性肿瘤联合治疗一部分的应用。与其他PI3K抑制剂相比，库潘尼西是一种独特的药物，在改善我们癌症治疗手段方面具有显著潜力。
